These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2413312)

  • 1. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB; Mardin M
    J Cardiovasc Pharmacol; 1985; 7(5):983-9. PubMed ID: 2413312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
    Bednar M; Smith B; Pinto A; Mullane KM
    Circ Res; 1985 Jul; 57(1):131-41. PubMed ID: 2988818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ; Murtagh JJ; Jolly SR; Abrams GD; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Jun; 102(1):63-70. PubMed ID: 6479219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
    Fiedler VB
    J Cardiovasc Pharmacol; 1984; 6(2):318-24. PubMed ID: 6200722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.
    Fiedler VB
    Basic Res Cardiol; 1983; 78(3):266-80. PubMed ID: 6615399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.
    Fiedler VB; Mardin M; Perzborn E; Grützmann R
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):267-74. PubMed ID: 3841382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of nafazatrom to reduce infarct size and arrhythmias in a porcine model of acute coronary occlusion.
    Fiedler VB
    Eur J Pharmacol; 1985 Aug; 114(2):189-95. PubMed ID: 3930268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Am Heart J; 1984 Apr; 107(4):629-37. PubMed ID: 6702555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoxygenase inhibitor nafazatrom fails to attenuate postischaemic ventricular dysfunction.
    O'Neill PG; Charlat ML; Kim HS; Pocius J; Michael LH; Hartley CJ; Zhu WX; Roberts R; Bolli R
    Cardiovasc Res; 1987 Oct; 21(10):755-60. PubMed ID: 3125975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of canine coronary collateral flow by nafazatrom.
    Fiedler VB; Mardin M
    Eur J Pharmacol; 1986 Nov; 130(3):157-67. PubMed ID: 3792445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds.
    Coker SJ; Parratt JR
    J Mol Cell Cardiol; 1984 Jan; 16(1):43-52. PubMed ID: 6366241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of halothane anesthesia on myocardial necrosis, hemodynamic performance, and regional myocardial blood flow in dogs following coronary artery occlusion.
    Davis RF; DeBoer LW; Rude RE; Lowenstein E; Maroko PR
    Anesthesiology; 1983 Nov; 59(5):402-11. PubMed ID: 6638546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of isoflurane on the extent of myocardial necrosis and on systemic hemodynamics, regional myocardial blood flow, and regional myocardial metabolism in dogs after coronary artery occlusion.
    Davis RF; Sidi A
    Anesth Analg; 1989 Nov; 69(5):575-86. PubMed ID: 2802193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs.
    Mullane KM; Read N; Salmon JA; Moncada S
    J Pharmacol Exp Ther; 1984 Feb; 228(2):510-22. PubMed ID: 6420544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L; Mehta J; Mehta P
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism.
    Ensley RD; Rubin LJ
    Prostaglandins Leukot Med; 1985 Apr; 18(1):95-104. PubMed ID: 3923499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional differences in postischemic recovery in the stunned canine myocardium.
    Farber NE; Pieper GM; Gross GJ
    Am Heart J; 1987 Nov; 114(5):1086-95. PubMed ID: 3673875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ortho-iodo sodium benzoate on acute myocardial ischemia, hemodynamic function, and infarct size after coronary artery occlusion in dogs.
    Rude RE; Tumas J; Gunst M; Kloner RA; DeBoer LW; Maroko PR
    Am J Cardiol; 1983 May; 51(8):1422-7. PubMed ID: 6846170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G; Bayorh MA; Stull R; Goldstein DS; Zerbe RL; Ramwell PW; Faden AI
    Circ Shock; 1985; 17(3):223-32. PubMed ID: 3841032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.